Welcome to our dedicated news page for Intra-Cellular Therapies (Ticker: ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intra-Cellular Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intra-Cellular Therapies's position in the market.
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced the successful completion of a public offering, including the full exercise of underwriters' option to purchase additional shares, resulting in gross proceeds of approximately $575 million. The offering involved the sale of 1,027,397 shares of common stock at $73.00 per share, following the initial offering of 6,849,316 shares. The underwriters included J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley, and RBC Capital Markets. The offering was made under a shelf registration statement on Form S-3 and the final prospectus supplement is available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. announced the pricing of its underwritten public offering of 6,849,316 shares of common stock at $73.00 per share, expecting gross proceeds of $500.0 million. The offering includes an option for additional shares, managed by top financial institutions. The public offering is made under a shelf registration statement on Form S-3, with the closing date set for April 22, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. announces a proposed public offering of $500 million of common stock, with the underwriters having a 30-day option to purchase additional shares. The offering is led by J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley, and RBC Capital Markets. The company filed a shelf registration statement with the SEC and will provide a preliminary prospectus supplement for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
Rhea-AI Summary
Intra-Cellular Therapies announces positive Phase 3 results for lumateperone as adjunctive therapy in patients with Major Depressive Disorder. Lumateperone 42 mg showed significant efficacy in primary and key secondary endpoints, with favorable safety and tolerability. The study demonstrated statistically significant reductions in depression symptoms compared to placebo, with a promising safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.29%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced the promotion of Michael Halstead, J.D. to President, overseeing key company functions. Larry Hineline, CFO, will retire after 20+ years of service, initiating a search for a replacement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (ITCI) is set to participate in three upcoming investor conferences to showcase their developments in CNS therapeutics. The company will present at Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and UBS Virtual CNS Day in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
Rhea-AI Summary
Intra-Cellular Therapies, Inc. announced that CEO Sharon Mates will present at the 44th Annual TD Cowen Health Care Conference. The presentation will focus on the development and commercialization of therapeutics for CNS disorders. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. reported strong financial results for 2023 with total revenues of $464.4 million, driven by CAPLYTA net product sales of $462.2 million, an 86% increase from 2022. The company provided a positive outlook for 2024 with expected net product sales of $645 to $675 million. Key clinical highlights include advancements in lumateperone programs for various disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. will host a conference call and live webcast discussion to provide a corporate update and discuss financial results for the quarter and year ended December 31, 2023. The event will take place on Thursday, February 22, 2024, at 8:30 a.m. Eastern Time. Participants can register for the conference call via a provided link and access the webcast on the Company's website. The focus of the call will be on the development and commercialization of therapeutics for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
Intra-Cellular Therapies Inc.
Nasdaq:ITCI
ITCI Rankings
ITCI Stock Data
7.62B
94.59M
2.51%
99.05%
3.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NEW YORK
About ITCI
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.